Success of Adjuvant Chemotherapy Trials for Gastric Cancer

  • Toshifusa Nakajima


Though surgery is the treatment modality of choice for many solid cancers, a rational approach seems to incorporate multimodal therapy into the treatment strategy for moderately locally advanced gastric cancer, as surgery cannot completely control micrometastasis. The rationale for adjuvant chemotherapy has been established by animal experiments [1, 2, 3], but the survival benefit of adjuvant chemotherapy is not always observed clinically for many solid cancers. The discrepancy between animal and clinical treatments should be thoroughly studied to improve the current treatment results. This paper reports the rationale for adjuvant chemotherapy derived from animal experiments, an analysis of the discrepancies between animal and clinical treatment results, and some discussion of possible pathways to future trials [4, 5, 6].


Gastric Cancer Adjuvant Chemotherapy Clin Oncol Tumor Burden Advanced Gastric Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Goldie J, Goldman A (1986) Application of theoretical models to chemotherapy protocol design. Cancer Treat Rep 70:127–131PubMedGoogle Scholar
  2. 2.
    Goldie J, Goldman A (1986) Theoretical considerations regarding the early use of adjuvant chemotherapy. Recent Results Cancer Res 103:30–35PubMedCrossRefGoogle Scholar
  3. 3.
    Schabel JF (1975) Concepts for systemic treatment of micrometastases. Cancer 35:15–24PubMedCrossRefGoogle Scholar
  4. 4.
    Collins JM (1984) Pharmacological rationale for regional drug delivery. J Clin Oncol 2:498–504PubMedGoogle Scholar
  5. 5.
    Speyer JL (1985) The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 12:23–28PubMedGoogle Scholar
  6. 6.
    Sugarbaker PH, Cunliffe WJ, Belliveau J, Bruijn EA, Graves T, Mullins RE, Schlag P (1989) Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 16:83–97PubMedGoogle Scholar
  7. 7.
    Skipper H, Schable FJ, Wilcox W (1964) Experimental evaluation of potential anticancer agent. XIII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother Rep 35:1–111PubMedGoogle Scholar
  8. 8.
    Nakajima T, Nishi M (1988) Adjuvant chemotherapy, immunochemotherapy, and neoadjuvant therapy for gastric cancer in Japan. In: Douglass HO Jr (ed) Gastric cancer. Churchill Livingstone, New York, pp 125–143Google Scholar
  9. 9.
    Douglass H Jr (1988) Western surgical adjuvant trials in gastric cancers: lessons from current trials to be applied to the future. In: Douglass HO, Jr (ed) Gastric cancer. Churchill Livingstone, New York, pp 145–172Google Scholar
  10. 10.
    Nakajima T (1995) Review of adjuvant chemotherapy for gastric cancer. World J Surg 19:570–574PubMedCrossRefGoogle Scholar
  11. 11.
    Hryniuk W, Levin MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162–1170PubMedGoogle Scholar
  12. 12.
    Ang P, Buzdar A, Smith T, Kau S, Hortobagyi GN (1989) Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast cancer. J Clin Oncol: 7:1677–1684PubMedGoogle Scholar
  13. 13.
    Elliott TE, Moertel CG, Wieand HS, Hahn R, Gerstner JB, Tschetter LK, Mailliard JA (1990) A phase II study of the combination of etoposide and cisplatin in the therapy of advanced cancer. Cancer 65:1491–1494PubMedCrossRefGoogle Scholar
  14. 14.
    Hayakawa M, Morise K, Chin K, Sugihara M, Morooka Y, Maeda H, Hattori T, Sato H (1994) Combination chemotherapy with tegafur-uracil (UFT) etoposide, adriamycin, and cisplatinum (UFT-EAP) for advanced gastric cancer. Jpn J Clin Oncol 24:282–288PubMedGoogle Scholar
  15. 15.
    Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, Akazawa S, Betsuyaku T, Ohkubo S, Takahashi H, Akiya T, Hamada T, Kiyohashi A (1993) A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 72:658–662PubMedCrossRefGoogle Scholar
  16. 16.
    Ohtsu A, Yoshida S, Saito D, Shimada Y, Miyamoto K, Fujii T, Yoshino M, Yoshimori M (1991) An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. Jpn J Clin Oncol 21:120–124PubMedGoogle Scholar
  17. 17.
    Preusser P, Wilke H, Achterrath W, Fink U, Meyer J, Meyer HJ, Van de Loo J (1987) Phase-II-Studie mit Etoposid, Adriamycin, Cisplatin (EAP) beim primaer inoperablen, metastasierten Magenkarzinom. Tumor Diagn Ther 8:43–48Google Scholar
  18. 18.
    Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer H-J, Buente H (1989) Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310–1317PubMedGoogle Scholar
  19. 19.
    Rougier P, Droz JP, Theodore C, Giot G (1987) Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma. Cancer Treat Rep 71:1301–1302PubMedGoogle Scholar
  20. 20.
    Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S (1997) Phase I–II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921–927PubMedGoogle Scholar
  21. 21.
    Horikoshi N, Mitachi Y, Sugimachi K, Taguchi T, Group S1CS (1996) New oral fluoropyrimidine is very active in patients with advanced gastric cancer (early phases II study). Proc ASCO 15:206Google Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Toshifusa Nakajima
    • 1
  1. 1.Department of SurgeryCancer Institute HospitalTokyoJapan

Personalised recommendations